TY - JOUR
T1 - Monoclonal gammopathy of undetermined significance and smouldering multiple myeloma
T2 - Emphasis on risk factors for progression
AU - Kyle, Robert A.
AU - Rajkumar, S. Vincent
PY - 2007/12
Y1 - 2007/12
N2 - Monoclonal gammopathy of undetermined significance (MGUS) is characterized by a serum monoclonal protein <30 g/l, <10% plasma cells in the bone marrow, and absence of end-organ damage (CRAB-hypercalcaemia, renal insufficiency, anaemia, or bone lesions). MGUS is present in 3% of persons >50 years and in 5% >70 years of age. The risk of progression to multiple myeloma (MM) or a related disorder is 1% per year. Patients with risk factors consisting of an abnormal serum free light chain ratio, non-immunoglobulin G (IgG) MGUS, and an elevated serum M protein ≥15 g/l had a risk of progression at 20 years of 58%, compared with 37% with two risk factors present, 21% with one risk factor present, and 5% when none of the risk factors were present. Smouldering (asymptomatic) multiple myeloma is characterized by having a serum IgG or IgA monoclonal protein of 30 g/l or higher and/or 10% or more plasma cells in the bone marrow but no evidence of end-organ damage. The cumulative probability of progression to active MM or amyloidosis was 51% at 5 years, 66% at 10 years and 73% at 15 years; the median time to progression was 4.8 years.
AB - Monoclonal gammopathy of undetermined significance (MGUS) is characterized by a serum monoclonal protein <30 g/l, <10% plasma cells in the bone marrow, and absence of end-organ damage (CRAB-hypercalcaemia, renal insufficiency, anaemia, or bone lesions). MGUS is present in 3% of persons >50 years and in 5% >70 years of age. The risk of progression to multiple myeloma (MM) or a related disorder is 1% per year. Patients with risk factors consisting of an abnormal serum free light chain ratio, non-immunoglobulin G (IgG) MGUS, and an elevated serum M protein ≥15 g/l had a risk of progression at 20 years of 58%, compared with 37% with two risk factors present, 21% with one risk factor present, and 5% when none of the risk factors were present. Smouldering (asymptomatic) multiple myeloma is characterized by having a serum IgG or IgA monoclonal protein of 30 g/l or higher and/or 10% or more plasma cells in the bone marrow but no evidence of end-organ damage. The cumulative probability of progression to active MM or amyloidosis was 51% at 5 years, 66% at 10 years and 73% at 15 years; the median time to progression was 4.8 years.
KW - Macroglobulinaemia
KW - Monoclonal gammopathy of undetermined significance
KW - Multiple myeloma
KW - Smouldering multiple myeloma
UR - http://www.scopus.com/inward/record.url?scp=36148952207&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=36148952207&partnerID=8YFLogxK
U2 - 10.1111/j.1365-2141.2007.06873.x
DO - 10.1111/j.1365-2141.2007.06873.x
M3 - Review article
C2 - 18021088
AN - SCOPUS:36148952207
SN - 0007-1048
VL - 139
SP - 730
EP - 743
JO - British journal of haematology
JF - British journal of haematology
IS - 5
ER -